AI-assisted, source-referenced information. Independent clinical review is pending. Our standards.
The short answer

The tablet removes the injection step, but semaglutide's systemic precautions remain. A useful review distinguishes side effects, difficulty following the tablet routine and the possibility of another illness.

Oral does not mean limited to the stomach

Wegovy tablets deliver semaglutide into the body and can cause digestive adverse effects including nausea, vomiting, diarrhoea and constipation. Report persistent or troublesome symptoms rather than assuming a tablet must be gentler than an injection. The prescriber needs to know how eating, fluid intake and normal activities are affected.

Give the exact tablet strength, when it was increased and how symptoms relate to doses. Avoid comparing your experience only with someone using a weekly injection. The formulations have different administration schedules, and another person's tolerability cannot establish what your symptoms mean.

Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: patient information leaflet; Novo Nordisk / electronic medicines compendium: Wegovy tablets: UK Summary of Product Characteristics

An administration problem and a side effect can coexist

Explain how the fasting and waiting instructions fit your day, including other oral medicines. If the routine is hard to follow, say which part is difficult. That information helps a clinician assess the treatment without assuming that every issue is solved by a higher dose or a stricter routine.

If vomiting occurs after a tablet, do not decide that the medicine was unabsorbed and take another one. Contact the pharmacist for advice about the event and future doses. Repeating a dose on an assumption can create a separate problem from the symptom that prompted it.

Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: patient information leaflet; Novo Nordisk / electronic medicines compendium: Wegovy tablets: UK Summary of Product Characteristics

Bring the other tablets into the review

The patient leaflet specifically highlights levothyroxine and oral anticoagulants such as warfarin as medicines to discuss; monitoring may need attention. Insulin or sulfonylureas also change the hypoglycaemia discussion. List every regular and occasional medicine rather than limiting the review to weight treatment.

Do not independently change an anticoagulant, thyroid medicine or diabetes treatment to accommodate symptoms. Ask the appropriate prescriber to coordinate the plan. If a new symptom starts after another prescription is added, report both changes so the assessment considers the combination and its timing.

Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: patient information leaflet; NHS: Low blood sugar: hypoglycaemia

Some symptoms require urgent assessment

Severe persistent abdominal pain, sometimes spreading to the back, needs urgent medical assessment. Repeated vomiting or diarrhoea with reduced urine, significant dizziness or inability to drink also needs prompt advice. Sudden vision loss warrants urgent eye casualty or A&E assessment under MHRA semaglutide guidance.

Call 999 for breathing difficulty, sudden swelling of the tongue or throat, or collapse suggesting a serious allergic reaction. Tell the treating team that the product is oral semaglutide and provide the last dose date. Do not wait for a routine online provider response to an emergency.

Sources: MHRA: GLP-1 medicines: strengthened warnings on acute pancreatitis; NHS: Dehydration: symptoms and when to get help; MHRA: MHRA updates semaglutide guidance on very rare NAION; NHS: Anaphylaxis: emergency symptoms and action

Make the review specific enough to act on

Ask whether symptoms change the next planned dose increase, whether monitoring is needed and when to contact the service again. Record the answer beside the medication schedule. If you have needed urgent care, send the assessment to the prescribing team before assuming the previous plan continues unchanged.

Discuss nutrition when appetite suppression has become difficulty meeting ordinary food needs. A tablet routine should support treatment, not conceal persistent illness or inadequate intake. Yellow Card reporting can document a suspected adverse effect, but it remains separate from getting clinical advice and a treatment plan.

Sources: NHS Bath and North East Somerset, Swindon and Wiltshire ICB: GLP-1 treatment: nutritional considerations for prescribing clinicians; Novo Nordisk / electronic medicines compendium: Wegovy tablets: UK Summary of Product Characteristics; MHRA: GLP-1 medicines for weight loss and diabetes: what you need to know

Questions, answered.

Can I take a replacement tablet after vomiting?

Do not repeat the dose on your own. Ask the pharmacist for advice, giving the tablet time and when vomiting occurred.

Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: patient information leaflet

Should the fasting routine be made stricter to manage symptoms?

Follow the prescribed instructions and discuss symptoms with the clinician. Self-imposed extra fasting is not a treatment for an unexplained adverse effect.

Sources: Novo Nordisk / electronic medicines compendium: Wegovy tablets: UK Summary of Product Characteristics

Sources & further reading

Original sources for this guide. Source checks are not independent clinical review.

  1. Wegovy tablets: patient information leafletNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
  2. Wegovy tablets: UK Summary of Product CharacteristicsNovo Nordisk / electronic medicines compendium · Accessed 19 November 2026
  3. Low blood sugar: hypoglycaemiaNHS · Accessed 19 November 2026
  4. GLP-1 medicines: strengthened warnings on acute pancreatitisMHRA · Accessed 19 November 2026
  5. Dehydration: symptoms and when to get helpNHS · Accessed 19 November 2026
  6. MHRA updates semaglutide guidance on very rare NAIONMHRA · Accessed 19 November 2026
  7. Anaphylaxis: emergency symptoms and actionNHS · Accessed 19 November 2026
  8. GLP-1 treatment: nutritional considerations for prescribing cliniciansNHS Bath and North East Somerset, Swindon and Wiltshire ICB · Accessed 19 November 2026
  9. GLP-1 medicines for weight loss and diabetes: what you need to knowMHRA · Accessed 19 November 2026